The American College of Surgeons Health Policy Research Institute

American College of Surgeons Health Policy Research Institute
Advancing Health Policy Information
for Surgery in the United States

How to Interpret CDC Inpatient Antibiotic Use Data

Hospital antibiotic use · NHSN measures

Inpatient antibiotic-use measures depend on patient-care location, antimicrobial category, reporting completeness and risk adjustment. A ratio or days-of-therapy rate is a stewardship signal, not a self-explanatory hospital ranking.

Editorial status: independent source analysis; see the research contributor directory.Source retrieved August 27, 2026

Two measures answer different questions

The CDC National Healthcare Safety Network Antimicrobial Use option collects standardized facility data. Days of therapy count days on which a patient receives a reportable antimicrobial, while use rates place those days over a defined denominator such as days present or admissions, depending on the measure and location.

The Standardized Antimicrobial Administration Ratio, or SAAR, compares observed antimicrobial days with predicted antimicrobial days for a specified agent category and patient-care context. CDC describes SAARs as risk-adjusted summary measures. The result depends on the applicable baseline and model.

Interpretation also needs a defined comparison question. A stewardship team may examine change within one location, variation across agent categories or performance against a national model; those analyses are not interchangeable.

Why a single number cannot rank hospitals

  • Facilities may serve different patient populations and clinical services.
  • Location mapping changes which encounters and denominators are included.
  • Agent categories answer narrower questions than total antibiotic use.
  • Incomplete or invalid submissions can distort interpretation.
  • A SAAR does not establish that any individual prescription was inappropriate.
Baseline versions matter

CDC updated the national antimicrobial-use baseline and risk-adjustment models for the 2023 SAAR rebaseline. Values generated under different baselines should not be presented as directly comparable without the agency’s method.

A reproducible reporting card

  1. Name the NHSN report, facility or group scope and data period.
  2. Record location, agent category, numerator and denominator.
  3. Identify SAAR baseline and risk-adjustment version if used.
  4. Document data-quality checks and missing reporting periods.
  5. Pair the metric with local clinical review before judging use.

What the metric cannot decide

Aggregate data can guide an antimicrobial-stewardship investigation. They cannot diagnose infection, select a medicine or determine whether a patient should continue therapy. Those questions require individual clinical information and qualified review.

Scroll to Top